Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.11 and traded as high as $5.91. Cumberland Pharmaceuticals shares last traded at $5.57, with a volume of 50,301 shares changing hands.

Analysts Set New Price Targets

CPIX has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen cut Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Trading Up 3.8%

The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.79 and a current ratio of 0.95. The firm has a 50-day moving average of $4.92 and a 200-day moving average of $4.14. The firm has a market capitalization of $90.65 million, a P/E ratio of -12.35 and a beta of 0.09.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in Cumberland Pharmaceuticals during the 2nd quarter valued at $34,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Cumberland Pharmaceuticals in the first quarter valued at about $66,000. Two Sigma Investments LP increased its position in shares of Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares during the period. Marshall Wace LLP bought a new position in shares of Cumberland Pharmaceuticals during the fourth quarter valued at about $192,000. Finally, Geode Capital Management LLC raised its stake in shares of Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 5,653 shares during the last quarter. 15.51% of the stock is currently owned by institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.